Devyser Diagnostics
75.60 SEK
-0.40 %
Less than 1K followers
DVYSR
First North Stockholm
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-0.40 %
-16.19 %
-33.80 %
-33.92 %
-46.15 %
-26.96 %
+8.00 %
-
-15.06 %
Devyser Diagnostics develops, manufactures, and sells genetic tests to laboratories globally. The products are used for DNA tests in oncology, transplantation, and hereditary diseases to enable tailored cancer treatment, diagnosis of a large number of genetic diseases, and follow-up of transplant patients. The company is headquartered in Hägersten.
Read moreMarket cap
1.26B SEK
Turnover
466.2K SEK
Revenue
250.5M
EBIT %
4.03 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
27.4
2026
Interim report Q1'26
6.5
2026
General meeting '26
20.7
2026
Interim report Q2'26
All
Webcasts
Press releases
ShowingAll content types
Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing
Redeye: Devyser (Q4 Interview): Redeye has interviewed CEO Jan Wahlström
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools

